The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: Systematic review and meta-analysis

Dolan, Ross D.; Lim, Jason Eng Kiat; McSorley, Stephen T.; Horgan, Paul G.; McMillan, Donald C.

doi:10.1038/s41598-017-16955-5

Cited by 220 publications

(241 citation statements)

References 254 publications

Supporting

Mentioning

231

Contrasting

Order By: Relevance

“…For lung cancer, evidence supports the prognostic value of NLR in advanced disease [18,19,20] and in early disease either treated with surgery or radiotherapy [30,31]. Nevertheless, its prognostic significance in EGFR-mutant advanced NSCLC has not been fully addressed, and almost all studies published to date have been conducted in Asian populations [20,22,23,24,25,26,27].…”

Section: Discussionmentioning

confidence: 99%

“…Several laboratory markers of SI have been confirmed as prognostic factors in many types of cancer, including plasma concentration of albumin, C-reactive protein, hemoglobin, platelets, and absolute values of white cells and its components (neutrophils, lymphocytes, monocytes) [16]. The neutrophil to lymphocyte ratio (NLR) is one of the most easy and inexpensive methods to estimate SI, and its value as a prognostic factor has been recognized in a wide variety of tumors, including NSCLC in both early and advanced stages [17,18,19,20,21]. However, information about the prognostic significance of NLR in EGFR-mutant advanced NSCLC is scarce, and almost all of the studies published to date have been conducted in Asian populations [20,22,23,24,25,26,27].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Neutrophil to Lymphocyte Ratio as a Prognostic Factor in European Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors

et al. 2018

View full text Add to dashboard Cite

Background: A high neutrophil to lymphocyte ratio (NLR) has been associated with adverse outcomes in non-small cell lung cancer (NSCLC). However, information on epidermal growth factor receptor (EGFR)-mutant advanced NSCLC is scarce, and most of the studies published have been conducted in Asian populations. We aimed to assess the influence of pretreatment NLR on progression-free survival (PFS) and overall survival (OS) in Western European patients treated with EGFR tyrosine kinase inhibitors (TKIs). Methods: A retrospective evaluation of 41 patients with EGFR-mutant advanced NSCLC treated with EGFR TKIs between June 2010 and May 2016 was carried out. The association between several prognostic factors including pretreatment NLR and survival was analyzed. Results: Median PFS and OS were 10.58 and 20.84 months, respectively. OS for patients with a high NLR was 7.4 months, compared to 24.6 months for patients with a low NLR (p = 0.0122). In multivariate analysis, poor performance status (ECOG PS ≥ 2) and presence of ≥ 3 metastatic locations were identified as significant independent prognostic factors for worse PFS. For OS, unfavorable prognostic factors were a high NLR and central nervous system metastasis at diagnosis. Conclusion: Pretreatment NLR is an independent prognostic factor for OS in Western European patients with EGFR-mutant NSCLC treated with EGFR TKIs.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Neutrophil to Lymphocyte Ratio as a Prognostic Factor in European Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors

et al. 2018

View full text Add to dashboard Cite

show abstract

“…All of the above events and conditions may result in heterogeneous sources of inflammation and oxidative stress [43,44,45,46,47,48] while impairing spontaneous physical activity, thereby synergistically enhancing muscle loss and dysfunction [49]. …”

Section: Introduction: What We Knowmentioning

confidence: 99%

Sarcopenic Obesity: Time to Meet the Challenge

et al. 2018

View full text Add to dashboard Cite

The prevalence of overweight and obesity has reached epidemic proportions worldwide due to increasingly pervasive obesogenic lifestyle changes. Obesity poses unprecedented individual, social, and multidisciplinary medical challenges by increasing the risk for metabolic diseases, chronic organ failures, and cancer as well as complication rates in the presence of acute disease conditions. Whereas reducing excess adiposity remains the fundamental pathogenic treatment for obese individuals, complex metabolic and lifestyle abnormalities as well as weight reduction therapies per se may also compromise the ability to preserve muscle function and mass, especially when chronic disease co-exists with obesity. Emerging evidence indicates that low muscle mass and quality have a strong negative prognostic impact in obese individuals and may lead to frailty, disability, and increased morbidity and mortality. Awareness of the importance of skeletal muscle maintenance in obesity is however low among clinicians and scientists. The term ‘sarcopenic obesity' has been proposed to identify obesity with low skeletal muscle function and mass, but its utilization is largely limited to the aging patient population, and consensus on its definition and diagnostic criteria remains insufficient. Knowledge on prevalence of sarcopenic obesity in various clinical conditions and patient subgroups, on its clinical impacts in patient risk stratification, and on effective prevention and treatment strategies remain therefore dramatically inadequate. In particular, optimal dietary options and medical nutritional support strategies to preserve muscle mass in obese individuals remain largely undefined. The European Society for Clinical Nutrition and Metabolism (ESPEN) and the European Association for the Study of Obesity (EASO) recognize and indicate obesity with altered body composition due to low skeletal muscle function and mass (sarcopenic obesity) as a scientific and clinical priority for researchers and clinicians. ESPEN and EASO therefore call for coordinated action aimed at reaching consensus on its definition, diagnostic criteria, and optimal treatment with particular regard to nutritional therapy. We are convinced that achievement of these goals has a strong potential to reduce the burden of morbidity and mortality in the rapidly increasing obese patient population.

show abstract

“…Cancer‐related inflammation is the seventh hallmark of cancer, with inflammatory cells and mediators, such as cytokines and chemokines, comprising an essential component of the tumor microenvironment . This inflammatory response is measured in the peripheral blood, and the SIR is associated with survival in patients with a variety of cancers …”

Section: Introductionmentioning

confidence: 99%

Role of systemic inflammatory response markers in urological malignancy

Ohno

2018

Int J of Urology

View full text Add to dashboard Cite

The systemic inflammatory response is associated with survival in patients with a variety of cancers. This inflammatory response is measured in the peripheral blood, and can be monitored using two categories of indices: concentration of specific serum proteins (albumin, C‐reactive protein) and differential blood cell count (neutrophils, lymphocytes and platelets). Furthermore, combinations of these indices, such as the Glasgow Prognostic Score, which consists of the serum C‐reactive protein and albumin level; the neutrophil‐to‐lymphocyte ratio; the platelet‐to‐lymphocyte ratio; and the prognostic nutritional index, which is based on peripheral blood lymphocyte count and serum albumin level, have also been evaluated and compared in cancer research. To date, there are hundreds of studies that have shown the prognostic value of systemic inflammatory response markers in patients with urological cancer. Most studies have evaluated the prognostic and predictive role of the pretreatment value of the markers, although some have focused on the role of the post‐treatment value at specific points during the clinical course. The advantages of systemic inflammatory response markers are that they are easily measurable and inexpensive in the clinical setting. However, it is important to consider how clinicians use these markers in clinical practice. The present review provides a concise overview regarding systemic inflammatory markers in urological cancers, specifically C‐reactive protein, Glasgow Prognostic Score/modified Glasgow Prognostic Score, neutrophil‐to‐lymphocyte ratio, platelet‐to‐lymphocyte ratio and prognostic nutritional index.

show abstract

The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: Systematic review and meta-analysis

Cited by 220 publications

References 254 publications

Neutrophil to Lymphocyte Ratio as a Prognostic Factor in European Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors

Neutrophil to Lymphocyte Ratio as a Prognostic Factor in European Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors

Sarcopenic Obesity: Time to Meet the Challenge

Role of systemic inflammatory response markers in urological malignancy

Contact Info

Product

Resources

About